Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Tr
about
Corticosteroid implants for chronic non-infectious uveitisBenefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and FollDissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up StudyCombined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma.Recent advances in managing and understanding uveitis.Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials."The patient is speaking": discovering the patient voice in ophthalmology.Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis.Pharmacologic Treatment of Noninfectious Uveitis.The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.Immunosuppression for the Uveitides.[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].Management of chronic ocular sarcoidosis: challenges and solutions.
P2860
Q24186144-DB4B4279-0D33-4C55-8DFF-C40DAFEA1066Q36090415-25C3FE88-214D-4C4B-8203-55D51127D8F0Q36739472-4D3456DE-8D9F-42D2-A17A-950535369D66Q37444765-3996CBC2-93B9-4F6E-B9D6-4ECCFB1ACE5CQ37709700-8B2B6404-FCF9-469C-9745-7DB6FA087A41Q38377111-C204A132-0D1E-4339-A6B4-D5BC1E04CFC1Q38377748-AF194466-B06A-4210-B2C1-E25BC6EDA8D1Q38689548-0D1C26A3-79A7-447C-9335-B26B5F737BC2Q38721223-25B7A854-161D-4CF9-AE8C-B56C5559AAE4Q40240534-B8445E76-EE99-43DF-9DE4-5AA9AB96FD39Q40450258-8DE2047C-4767-49FC-87AD-FAA115789E25Q47737232-BF031A4C-5E0C-43A2-8624-432DEBBCCE21Q47932596-0D206F58-71E4-4696-8B84-5F9DCAF1852CQ49845401-F56C6E54-F4A0-43CC-955A-736038C1DFB5Q52338865-79183774-9E6C-45F8-A68C-4E4E490E65BC
P2860
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Tr
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@ast
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@en
type
label
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@ast
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@en
prefLabel
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@ast
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@en
P2860
P921
P1433
P1476
Quality of Life and Risks Asso ...... Multicenter Uveitis Steroid Tr
@en
P2093
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
P2860
P304
P356
10.1016/J.OPHTHA.2015.06.043
P577
2015-08-19T00:00:00Z